Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
JANX Financials Janux Therapeutics, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | -$114M | 0.0% | -1576.7% | -$83M | — | $52M |
| 2024 | $11M | -$69M | 0.0% | -933.6% | -$44M | — | $431M |
| 2023 | $8M | -$58M | 0.0% | -902.9% | -$52M | — | $19M |
| 2022 | $9M | -$63M | 0.0% | -779.0% | -$49M | — | $51M |
| 2021 | $4M | -$33M | 0.0% | -905.4% | -$18M | — | $36M |
| 2020 | $0 | -$7M | — | — | -$4M | — | $8M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $4M | -$24M | 0.0% | -916.5% | -$13M | — | $52M |
| Dec '25 | $0 | -$32M | — | — | -$29M | — | $52M |
| Sep '25 | $10M | -$24M | 0.0% | -352.5% | -$13M | — | $48M |
| Jun '25 | $0 | -$34M | — | — | -$24M | — | $52M |
| Mar '25 | $0 | -$24M | — | — | -$17M | — | $74M |
| Dec '24 | $0 | -$20M | — | — | -$17M | — | $431M |
| Sep '24 | $439000 | -$28M | 0.0% | -8164.5% | -$2M | — | $27M |
| Jun '24 | $9M | -$6M | 0.0% | -155.4% | -$10M | — | $15M |
| Mar '24 | $1M | -$15M | 0.0% | -1610.3% | -$15M | — | $213M |
| Dec '23 | $2M | -$12M | 0.0% | -655.7% | -$10M | — | $19M |
| Sep '23 | $3M | -$12M | 0.0% | -628.2% | -$12M | — | $17M |
| Jun '23 | $1M | -$18M | 0.0% | -1962.9% | -$16M | — | $34M |
| Mar '23 | $2M | -$17M | 0.0% | -990.3% | -$14M | — | $30M |
| Dec '22 | $3M | -$16M | 0.0% | -642.0% | -$14M | — | $51M |
| Sep '22 | $2M | -$17M | 0.0% | -994.0% | -$16M | — | $65M |
| Jun '22 | $2M | -$17M | 0.0% | -729.9% | -$7M | — | $58M |
| Mar '22 | $2M | -$13M | 0.0% | -852.2% | -$12M | — | $55M |
| Dec '21 | $2M | -$13M | 0.0% | -834.8% | -$12M | — | $36M |
| Sep '21 | $1M | -$11M | 0.0% | -940.7% | -$6M | — | $39M |
| Jun '21 | $482000 | -$6M | 0.0% | -1297.1% | -$6M | — | $252M |
Valuation over time
How the market has priced JANX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 85.7× (Mar '23) to 88.7× (Jun '26).
P/S
Frequently asked questions
Is JANX growing its revenue and profit?
See the revenue and net-income charts above for Janux Therapeutics, Inc.'s multi-year trend.
How much debt does JANX have?
As of FY2025, Janux Therapeutics, Inc. reported — of total debt against $52M of cash.
What is JANX's profit margin?
In FY2025, gross margin was —, operating margin -1576.7%, and net margin -1136.3%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.